Federated Hermes Inc. Sells 356,632 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Federated Hermes Inc. trimmed its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 86.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,340 shares of the medical instruments supplier's stock after selling 356,632 shares during the quarter. Federated Hermes Inc. owned about 0.07% of OraSure Technologies worth $446,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of OSUR. SG Americas Securities LLC boosted its stake in shares of OraSure Technologies by 235.1% in the third quarter. SG Americas Securities LLC now owns 41,982 shares of the medical instruments supplier's stock valued at $249,000 after buying an additional 29,452 shares during the period. Simplicity Solutions LLC grew its stake in OraSure Technologies by 146.4% during the third quarter. Simplicity Solutions LLC now owns 40,036 shares of the medical instruments supplier's stock worth $237,000 after buying an additional 23,789 shares in the last quarter. Inspire Investing LLC bought a new position in OraSure Technologies in the 3rd quarter valued at about $670,000. Allspring Global Investments Holdings LLC raised its position in shares of OraSure Technologies by 421.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 384,439 shares of the medical instruments supplier's stock valued at $2,280,000 after buying an additional 310,715 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its holdings in shares of OraSure Technologies by 22.4% during the 3rd quarter. Panagora Asset Management Inc. now owns 387,368 shares of the medical instruments supplier's stock worth $2,297,000 after acquiring an additional 70,894 shares during the period. Institutional investors and hedge funds own 93.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. StockNews.com raised shares of OraSure Technologies from a "hold" rating to a "buy" rating in a research note on Wednesday. Evercore ISI decreased their price target on OraSure Technologies from $7.00 to $6.50 and set an "in-line" rating on the stock in a research note on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, OraSure Technologies presently has an average rating of "Moderate Buy" and a consensus target price of $6.38.

OraSure Technologies Trading Up 0.2 %

OraSure Technologies stock traded up $0.01 during mid-day trading on Friday, reaching $5.49. The company had a trading volume of 668,077 shares, compared to its average volume of 687,993. The business has a fifty day simple moving average of $6.18 and a 200 day simple moving average of $6.80. The company has a market cap of $420.04 million, a P/E ratio of 7.63 and a beta of 0.23. OraSure Technologies, Inc. has a fifty-two week low of $4.38 and a fifty-two week high of $8.45.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last posted its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 EPS for the quarter, beating the consensus estimate of $0.13 by $0.09. The firm had revenue of $75.88 million during the quarter, compared to the consensus estimate of $74.13 million. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The business's quarterly revenue was down 38.3% on a year-over-year basis. During the same period last year, the company earned $0.21 earnings per share. Research analysts forecast that OraSure Technologies, Inc. will post -0.11 EPS for the current year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.